These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37208330)

  • 1. saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern.
    Komori M; Nogimori T; Morey AL; Sekida T; Ishimoto K; Hassett MR; Masuta Y; Ode H; Tamura T; Suzuki R; Alexander J; Kido Y; Matsuda K; Fukuhara T; Iwatani Y; Yamamoto T; Smith JF; Akahata W
    Nat Commun; 2023 May; 14(1):2810. PubMed ID: 37208330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity.
    McCafferty S; Haque AKMA; Vandierendonck A; Weidensee B; Plovyt M; Stuchlíková M; François N; Valembois S; Heyndrickx L; Michiels J; Ariën KK; Vandekerckhove L; Abdelnabi R; Foo CS; Neyts J; Sahu I; Sanders NN
    Mol Ther; 2022 Sep; 30(9):2968-2983. PubMed ID: 35450821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern.
    Xu J; Zhang Y; Qu P; Shamseldin MM; Yoo SJ; Misny J; Thongpan I; Kc M; Hall JM; Evans JP; Eltobgy M; Lu M; Ye C; Chamblee M; Liang X; Martinez-Sobrido L; Amer AO; Yount JS; Boyaka PN; Peeples ME; Liu SL; Dubey P; Li J
    Proc Natl Acad Sci U S A; 2023 Oct; 120(41):e2220403120. PubMed ID: 37796985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.
    Deliyannis G; Gherardin NA; Wong CY; Grimley SL; Cooney JP; Redmond SJ; Ellenberg P; Davidson KC; Mordant FL; Smith T; Gillard M; Lopez E; McAuley J; Tan CW; Wang JJ; Zeng W; Littlejohn M; Zhou R; Fuk-Woo Chan J; Chen ZW; Hartwig AE; Bowen R; Mackenzie JM; Vincan E; Torresi J; Kedzierska K; Pouton CW; Gordon TP; Wang LF; Kent SJ; Wheatley AK; Lewin SR; Subbarao K; Chung AW; Pellegrini M; Munro T; Nolan T; Rockman S; Jackson DC; Purcell DFJ; Godfrey DI
    EBioMedicine; 2023 Jun; 92():104574. PubMed ID: 37148585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs.
    Liu Z; Zhou J; Xu W; Deng W; Wang Y; Wang M; Wang Q; Hsieh M; Dong J; Wang X; Huang W; Xing L; He M; Tao C; Xie Y; Zhang Y; Wang Y; Zhao J; Yuan Z; Qin C; Jiang S; Lu L
    Cell Res; 2022 Mar; 32(3):269-287. PubMed ID: 35046518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
    Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
    J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models.
    Maruggi G; Mallett CP; Westerbeck JW; Chen T; Lofano G; Friedrich K; Qu L; Sun JT; McAuliffe J; Kanitkar A; Arrildt KT; Wang KF; McBee I; McCoy D; Terry R; Rowles A; Abrahim MA; Ringenberg MA; Gains MJ; Spickler C; Xie X; Zou J; Shi PY; Dutt T; Henao-Tamayo M; Ragan I; Bowen RA; Johnson R; Nuti S; Luisi K; Ulmer JB; Steff AM; Jalah R; Bertholet S; Stokes AH; Yu D
    Mol Ther; 2022 May; 30(5):1897-1912. PubMed ID: 34990810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
    Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
    Front Immunol; 2022; 13():816389. PubMed ID: 35464418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of novel DNA vaccines encoding receptor-binding domain (RBD) dimer-Fc fusing antigens derived from different SARS-CoV-2 variants of concern.
    Zhang T; Wang Z; Yang J; Xu X
    J Med Virol; 2023 Feb; 95(2):e28563. PubMed ID: 36755368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A vaccine delivery system promotes strong immune responses against SARS-CoV-2 variants.
    Lei Z; Zhu L; Pan P; Ruan Z; Gu Y; Xia X; Wang S; Ge W; Yao Y; Luo F; Xiao H; Guo J; Ding Q; Yin Z; Li Y; Luo Z; Zhang Q; Chen X; Wu J
    J Med Virol; 2023 Feb; 95(2):e28475. PubMed ID: 36606607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern.
    Lee IJ; Lan YH; Wu PY; Wu YW; Chen YH; Tseng SC; Kuo TJ; Sun CP; Jan JT; Ma HH; Liao CC; Liang JJ; Ko HY; Chang CS; Liu WC; Ko YA; Chen YH; Sie ZL; Tsung SI; Lin YL; Wang IH; Tao MH
    Emerg Microbes Infect; 2023 Dec; 12(1):2149353. PubMed ID: 36395071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters.
    Boudewijns R; Pérez P; Lázaro-Frías A; Van Looveren D; Vercruysse T; Thibaut HJ; Weynand B; Coelmont L; Neyts J; Astorgano D; Montenegro D; Puentes E; Rodríguez E; Dallmeier K; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():845969. PubMed ID: 35371064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine.
    Hawman DW; Meade-White K; Clancy C; Archer J; Hinkley T; Leventhal SS; Rao D; Stamper A; Lewis M; Rosenke R; Krieger K; Randall S; Khandhar AP; Hao L; Hsiang TY; Greninger AL; Gale M; Berglund P; Fuller DH; Rosenke K; Feldmann H; Erasmus JH
    EBioMedicine; 2022 Sep; 83():104196. PubMed ID: 35932641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
    Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
    Front Immunol; 2022; 13():908478. PubMed ID: 35844601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circular RNA vaccines against SARS-CoV-2 and emerging variants.
    Qu L; Yi Z; Shen Y; Lin L; Chen F; Xu Y; Wu Z; Tang H; Zhang X; Tian F; Wang C; Xiao X; Dong X; Guo L; Lu S; Yang C; Tang C; Yang Y; Yu W; Wang J; Zhou Y; Huang Q; Yisimayi A; Liu S; Huang W; Cao Y; Wang Y; Zhou Z; Peng X; Wang J; Xie XS; Wei W
    Cell; 2022 May; 185(10):1728-1744.e16. PubMed ID: 35460644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose rAAV5-based vaccine provides long-term protective immunity against SARS-CoV-2 and its variants.
    Liao G; Lau H; Liu Z; Li C; Xu Z; Qi X; Zhang Y; Feng Q; Li R; Deng X; Li Y; Zhu Q; Zhu S; Zhou H; Pan H; Fan X; Li Y; Li D; Chen L; Ke B; Cong Z; Lv Q; Liu J; Liang D; Li A; Hong W; Bao L; Zhou F; Gao H; Liang S; Huang B; Wu M; Qin C; Ke C; Liu L
    Virol J; 2022 Dec; 19(1):212. PubMed ID: 36494863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2.
    Jawalagatti V; Kirthika P; Hewawaduge C; Yang MS; Park JY; Oh B; Lee JH
    Mol Ther; 2022 May; 30(5):1926-1940. PubMed ID: 35123065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.